Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379280901> ?p ?o ?g. }
- W4379280901 endingPage "8554" @default.
- W4379280901 startingPage "8554" @default.
- W4379280901 abstract "8554 Background: Surgery is standard of care for patients with stage I non-small cell lung cancer (NSCLC). However, 5-year mortality can reach up to 30%. For patients with contraindication to surgery, treatment with stereotactic ablative radiotherapy (SABR) leads to adequate local tumor control, but has a high rate of regional and distant failure. SABR as neoadjuvant therapy for stage I NSCLC produced a pathologic complete response (pCR) rate of only 60% when surgery was performed after 10 weeks of treatment, demanding improvement in the management of both operable and inoperable early-stage NSCLC. Immune checkpoint inhibitors (ICI) are routinely used in stages III-IV NSCLC, with recent approvals in the peri-operative setting, and may be synergistic with radiotherapy. We hypothesized that neoadjuvant nivolumab plus SABR may improve pCR rate and provide insight to its changes in the tumor microenvironment. Methods: This is a phase 2, single arm, open label study evaluating neoadjuvant treatment for patients with NSCLC of up to 4 cm, with no lymph node involvement (AJCC 8th edition: up to cT2aN0), and adequate surgical conditions. Treatment consisted of nivolumab 360 mg every 3 weeks for 3 doses or unacceptable toxicity. SABR started on D1 of nivolumab, with a duration of 2 to 3 weeks, depending on the lesion size and location (3 x 18 Gy; or 5 x 10 Gy; or 8 x 7.5 Gy). Standard-of-care surgery was performed at 10 (+- 2) weeks after the last radiotherapy dose. The primary endpoint of the study is pCR rate at surgery. Tissue, blood, and stool samples were collected during treatment. Results: We included 25 patients. All but one were cared for in the Brazilian public system. Mean age was 68 years. Mean tumor size was 2.45 cm. Only 3 patients were never-smokers. Surgery was performed as scheduled in all but one patient. pCR rate was 80% (19/24) and MPR rate was 83% (20/24) of patients who underwent surgery. Twenty-nine treatment-emergent adverse events occurred in 13 patients (23 grade 1-2 events, two grade 3 and two grade 5 events, being only one grade 3 diarrhea related to experimental treatment). The single patient who was not operated died during study treatment from relapsed acute alcoholic hepatitis. The other grade 5 event was due to a respiratory infection, both unrelated to treatment. Two patients died from surgical complications 185 and 72 days after surgery, respectively (one with pulmonary artery lesion with subsequent clinical complications and other with thromboembolic events), deemed unrelated to experimental treatment. During follow-up, two additional patients died due to comorbidities, and none relapsed to date. Conclusions: In this trial with patients with significant comorbidities and smoking history from the public system in Brazil, we demonstrated a pCR rate of 80% with SABR + nivolumab. Further studies are warranted to evaluate this strategy versus surgery in operable patients with stage I disease. Clinical trial information: NCT04271384 ." @default.
- W4379280901 created "2023-06-05" @default.
- W4379280901 creator A5000161940 @default.
- W4379280901 creator A5001070802 @default.
- W4379280901 creator A5012537611 @default.
- W4379280901 creator A5017588406 @default.
- W4379280901 creator A5023231481 @default.
- W4379280901 creator A5041896298 @default.
- W4379280901 creator A5042241281 @default.
- W4379280901 creator A5050158719 @default.
- W4379280901 creator A5051440630 @default.
- W4379280901 creator A5058611909 @default.
- W4379280901 creator A5064230679 @default.
- W4379280901 creator A5064335194 @default.
- W4379280901 creator A5065440577 @default.
- W4379280901 creator A5069695086 @default.
- W4379280901 creator A5080217170 @default.
- W4379280901 creator A5082994226 @default.
- W4379280901 creator A5089098509 @default.
- W4379280901 date "2023-06-01" @default.
- W4379280901 modified "2023-10-01" @default.
- W4379280901 title "Stereotactic ablative radiotherapy with nivolumab for early-stage operable non-small cell lung cancer: A phase 2 study." @default.
- W4379280901 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.8554" @default.
- W4379280901 hasPublicationYear "2023" @default.
- W4379280901 type Work @default.
- W4379280901 citedByCount "0" @default.
- W4379280901 crossrefType "journal-article" @default.
- W4379280901 hasAuthorship W4379280901A5000161940 @default.
- W4379280901 hasAuthorship W4379280901A5001070802 @default.
- W4379280901 hasAuthorship W4379280901A5012537611 @default.
- W4379280901 hasAuthorship W4379280901A5017588406 @default.
- W4379280901 hasAuthorship W4379280901A5023231481 @default.
- W4379280901 hasAuthorship W4379280901A5041896298 @default.
- W4379280901 hasAuthorship W4379280901A5042241281 @default.
- W4379280901 hasAuthorship W4379280901A5050158719 @default.
- W4379280901 hasAuthorship W4379280901A5051440630 @default.
- W4379280901 hasAuthorship W4379280901A5058611909 @default.
- W4379280901 hasAuthorship W4379280901A5064230679 @default.
- W4379280901 hasAuthorship W4379280901A5064335194 @default.
- W4379280901 hasAuthorship W4379280901A5065440577 @default.
- W4379280901 hasAuthorship W4379280901A5069695086 @default.
- W4379280901 hasAuthorship W4379280901A5080217170 @default.
- W4379280901 hasAuthorship W4379280901A5082994226 @default.
- W4379280901 hasAuthorship W4379280901A5089098509 @default.
- W4379280901 hasConcept C106159729 @default.
- W4379280901 hasConcept C121608353 @default.
- W4379280901 hasConcept C126322002 @default.
- W4379280901 hasConcept C141071460 @default.
- W4379280901 hasConcept C142724271 @default.
- W4379280901 hasConcept C143998085 @default.
- W4379280901 hasConcept C146357865 @default.
- W4379280901 hasConcept C151730666 @default.
- W4379280901 hasConcept C162324750 @default.
- W4379280901 hasConcept C187625094 @default.
- W4379280901 hasConcept C203092338 @default.
- W4379280901 hasConcept C204787440 @default.
- W4379280901 hasConcept C2776256026 @default.
- W4379280901 hasConcept C2776494729 @default.
- W4379280901 hasConcept C2777701055 @default.
- W4379280901 hasConcept C2778292576 @default.
- W4379280901 hasConcept C2780030458 @default.
- W4379280901 hasConcept C2780849966 @default.
- W4379280901 hasConcept C509974204 @default.
- W4379280901 hasConcept C530470458 @default.
- W4379280901 hasConcept C535046627 @default.
- W4379280901 hasConcept C71924100 @default.
- W4379280901 hasConcept C85393063 @default.
- W4379280901 hasConcept C86803240 @default.
- W4379280901 hasConcept C91602232 @default.
- W4379280901 hasConceptScore W4379280901C106159729 @default.
- W4379280901 hasConceptScore W4379280901C121608353 @default.
- W4379280901 hasConceptScore W4379280901C126322002 @default.
- W4379280901 hasConceptScore W4379280901C141071460 @default.
- W4379280901 hasConceptScore W4379280901C142724271 @default.
- W4379280901 hasConceptScore W4379280901C143998085 @default.
- W4379280901 hasConceptScore W4379280901C146357865 @default.
- W4379280901 hasConceptScore W4379280901C151730666 @default.
- W4379280901 hasConceptScore W4379280901C162324750 @default.
- W4379280901 hasConceptScore W4379280901C187625094 @default.
- W4379280901 hasConceptScore W4379280901C203092338 @default.
- W4379280901 hasConceptScore W4379280901C204787440 @default.
- W4379280901 hasConceptScore W4379280901C2776256026 @default.
- W4379280901 hasConceptScore W4379280901C2776494729 @default.
- W4379280901 hasConceptScore W4379280901C2777701055 @default.
- W4379280901 hasConceptScore W4379280901C2778292576 @default.
- W4379280901 hasConceptScore W4379280901C2780030458 @default.
- W4379280901 hasConceptScore W4379280901C2780849966 @default.
- W4379280901 hasConceptScore W4379280901C509974204 @default.
- W4379280901 hasConceptScore W4379280901C530470458 @default.
- W4379280901 hasConceptScore W4379280901C535046627 @default.
- W4379280901 hasConceptScore W4379280901C71924100 @default.
- W4379280901 hasConceptScore W4379280901C85393063 @default.
- W4379280901 hasConceptScore W4379280901C86803240 @default.
- W4379280901 hasConceptScore W4379280901C91602232 @default.
- W4379280901 hasIssue "16_suppl" @default.
- W4379280901 hasLocation W43792809011 @default.
- W4379280901 hasOpenAccess W4379280901 @default.
- W4379280901 hasPrimaryLocation W43792809011 @default.